Evidence map›Paper›PMID 35136953›Full record

ArticleBrain : a journal of neurology2022

NPRL3 loss alters neuronal morphology, mTOR localization, cortical lamination and seizure threshold.

Philip H Iffland, Mariah E Everett, Katherine M Cobb-Pitstick, Lauren E Bowser, Allan E Barnes, Janice K Babus, Andrea J Romanowski, Marianna Baybis, Soad Elziny, Erik G Puffenberger and 4 more

Open access · bronzeAbstract read
In one paragraph

Article in Brain : a journal of neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 32 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. NovelFrontiers in neuroscience · 2025
    Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Loss ofbioRxiv : the preprint server for biology · 2023
    Article
  17. Review
  18. Hemimegalencephaly and intractable focal seizures related toAnnals of the Child Neurology Society · 2023
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Philip H IfflandUniversity of Maryland School of Medicine Departments of Neurology and Pharmacology, Baltimore, MD 21201, USA.
Mariah E EverettClinic for Special Children, Strasburg, PA 17579, USA.
Katherine M Cobb-PitstickUPMC Children's Hospital of Pittsburgh Department of Neurology, Pittsburgh, PA 15224, USA.
Lauren E BowserClinic for Special Children, Strasburg, PA 17579, USA.
Allan E BarnesUniversity of Maryland School of Medicine Departments of Neurology and Pharmacology, Baltimore, MD 21201, USA.
Janice K BabusUniversity of Maryland School of Medicine Departments of Neurology and Pharmacology, Baltimore, MD 21201, USA.
Andrea J RomanowskiUniversity of Maryland School of Medicine Departments of Neurology and Pharmacology, Baltimore, MD 21201, USA.
Marianna BaybisUniversity of Maryland School of Medicine Departments of Neurology and Pharmacology, Baltimore, MD 21201, USA.
Soad ElzinyUniversity of Maryland School of Medicine Departments of Neurology and Pharmacology, Baltimore, MD 21201, USA.
Erik G PuffenbergerClinic for Special Children, Strasburg, PA 17579, USA.
Claudia Gonzaga-JaureguiRegeneron Genetics Center, Regeneron Pharmaceuticals Inc., Tarrytown, New York, 10591, USA.
Alexandros PoulopoulosUniversity of Maryland School of Medicine Departments of Neurology and Pharmacology, Baltimore, MD 21201, USA.
Vincent J CarsonClinic for Special Children, Strasburg, PA 17579, USA.
Peter B CrinoUniversity of Maryland School of Medicine Departments of Neurology and Pharmacology, Baltimore, MD 21201, USA.
University of Maryland, Baltimore · USClinic for Special Children · USChildren's Hospital of Pittsburgh · USRegeneron (United States) · US

Funding

Identification and molecular characterization of somatic mutations in MCDR01NS094596 · NINDS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Peter B Crino, Erin L HEINZEN · 2016 to 2026
$5.9M
Defining disease mechanisms in SLC35A2 epilepsyR01NS115017 · NINDS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CRINO, PETER B, HEINZEN, ERIN L · 2020 to 2024
$3.7M
Untangling the biology of brain wiring: high-throughput innovations for molecular screening and functional targeting of circuit development in vivoDP2MH122398 · NIMH · UNIVERSITY OF MARYLAND BALTIMORE · PI POULOPOULOS, ALEXANDROS · 2019 to 2019
$2.3M
The Role of GATOR1 in Cortical MalformationsR01NS099452 · NINDS · UNIVERSITY OF MARYLAND BALTIMORE · PI CRINO, PETER B · 2017 to 2021
$1.7M
NIMH NIH HHS DP2 MH122398NINDS NIH HHS R01 NS094596NINDS NIH HHS R01 NS099452NINDS NIH HHS R01 NS115017
6 · The paper itself

Abstract

Mutations in nitrogen permease regulator-like 3 (NPRL3), a component of the GATOR1 complex within the mTOR pathway, are associated with epilepsy and malformations of cortical development. Little is known about the effects of NPRL3 loss on neuronal mTOR signalling and morphology, or cerebral cortical development and seizure susceptibility. We report the clinical phenotypic spectrum of a founder NPRL3 pedigree (c.349delG, p.Glu117LysFS; n = 133) among Old Order Mennonites dating to 1727. Next, as a strategy to define the role of NPRL3 in cortical development, CRISPR/Cas9 Nprl3 knockout in Neuro2a cells in vitro and in foetal mouse brain in vivo was used to assess the effects of Nprl3 knockout on mTOR activation, subcellular mTOR localization, nutrient signalling, cell morphology and aggregation, cerebral cortical cytoarchitecture and network integrity. The NPRL3 pedigree exhibited an epilepsy penetrance of 28% and heterogeneous clinical phenotypes with a range of epilepsy semiologies, i.e. focal or generalized onset, brain imaging abnormalities, i.e. polymicrogyria, focal cortical dysplasia or normal imaging, and EEG findings, e.g. focal, multi-focal or generalized spikes, focal or generalized slowing. Whole exome analysis comparing a seizure-free group (n = 37) to those with epilepsy (n = 24) to search for gene modifiers for epilepsy did not identify a unique genetic modifier that explained the variability in seizure penetrance in this cohort. Nprl3 knockout in vitro caused mTOR pathway hyperactivation, cell soma enlargement and the formation of cellular aggregates seen in time-lapse videos that were prevented with the mTOR inhibitors rapamycin or torin1. In Nprl3 knockout cells, mTOR remained localized on the lysosome in a constitutively active conformation, as evidenced by phosphorylation of ribosomal S6 and 4E-BP1 proteins, even under nutrient starvation (amino acid-free) conditions, demonstrating that Nprl3 loss decouples mTOR activation from neuronal metabolic state. To model human malformations of cortical development associated with NPRL3 variants, we created a focal Nprl3 knockout in foetal mouse cortex by in utero electroporation and found altered cortical lamination and white matter heterotopic neurons, effects which were prevented with rapamycin treatment. EEG recordings showed network hyperexcitability and reduced seizure threshold to pentylenetetrazol treatment. NPRL3 variants are linked to a highly variable clinical phenotype which we propose results from mTOR-dependent effects on cell structure, cortical development and network organization.

Indexed as

EpilepsyMalformations of Cortical DevelopmentAnimalsGTPase-Activating ProteinsHumansMiceNeuronsSeizuresSirolimusTOR Serine-Threonine KinasesGTPase-Activating ProteinsMTOR protein, humanNPRL3 protein, humanNprl3 protein, mouseSirolimusTOR Serine-Threonine Kinasescortical malformationsepilepsyfocal cortical dysplasiaGATOR1mTOR

Identifiers

PMID35136953
PMCPMC10200289
OpenAlexW4210242813

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.